Search Results
Interoception and eating behaviors in children
The purpose of this study is to examine how individual differences in interoception (the ability to sense, interpret, and act on bodily feelings like hunger, fullness, thirst, hot, cold, etc.) relate to eating behaviors in children ages 7-10 years. Findings will inform whether interventions targeting interoceptive awareness may be helpful for prevention of obesity and related chronic diseases.
Child and parent will attend 2 visits at the Clinical Research Center, about 1-3 weeks apart.At visit 1 (~3 hours)- Your child's height and weight will be measured- Your child's percent body fat will be measured using an x-ray based technology- Your child will wear a heart rate monitor and will complete tasks where they are asked to notice or count their heartbeat- Your child will complete questionnaires via an interview with a researcher- Your child will be asked to drink several glasses of water to measure their stomach sensations- You will complete questionnairesAt visit 2 (~2.5 hours)- We will collect 4 saliva samples from your child- Your child will eat a meal and taste snacks- Your child will play brain games on an iPad- You will complete questionnaires
$100
Able to understand and answer questions in English
Any medical conditions impacting growth, eating, or heart function
Developmental delay
Autism/autism spectrum disorder
Taking medications that impact appetite
An exploratory analysis of commuting satisfaction and travel mode dissonance
The purpose of this research is to explore commuting mobility patterns and satisfaction levels among commuters in different regions and demographics. The study aims to identify barriers to current commuting practices, evaluate commuter opinions and intentions, and understand the implications of travel mode dissonance on commuter satisfaction and overall well-being. This research will also investigate how future commuting policies can incentivize sustainable commuting practices, ultimately aiming to reduce commuting emissions.
Participants will be required to complete an online survey, which will take approximately 10-15 minutes. All responses are anonymous, and participants may choose to skip any questions or exit the survey at any time without providing a reason.
Are over the age of 18
Are working or going to school (i.e., conducting a commute trip)
Use transportation systems
Children under 18 years
Individuals who do not work
PSCI 24-077 A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PI3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor
this trial is looking at introducing a medication to control blood sugars elevations caused by CDK inhibitors.
Participants must agree to come to all study visits, report any new medications to the study team, agree to having blood work done at least 8-12 hours after eating something, take study medication as directed.
Patient with histologically and/or cytologically confirmed diagnosis of HR+, HER2- breast cancer, as determined by the local laboratory.
Patient has identified PI3K pathway
Patient has locally advanced (not amenable to curative therapy or metastatic) breast cancer meeting any of the following categories:
Patient has measurable disease
Patient has known primary brain malignancy,
Patient has a known hypersensitivity to evexomostat, fulvestrant, alpelisib or capivasertib, or to any of their excipients.
Patient has had major surgery within 30 days
Patient has uncontrolled human immunodeficiency virus (HIV) infection.
Locomotor Learning in Exoskeleton-Assisted Walking
The goal of this study is to explore how different ways of practicing, as well as paying attention, affect learning to walk while using an ankle exoskeleton. This pilot study will look at whether changing the settings of the exoskeleton and walking conditions frequently or not very often helps people walk better in follow-up tests. It will also examine if asking people to focus on their body (internal focus) or on their surroundings (external focus) improves their walking.
There will be three in-person visits over two days, walking in a lower limb exoskeleton will occur at all three visits.
$40.00
Normal ankle functionality
Age: 18-40 years old
Responsiveness: Subjects must be able to follow verbal instructions
Shoe size: Fit shoes sizes 6-10 (men) or 7-11 (women)
Previous or existing lower limb musculoskeletal injuries or conditions (e.g. joint replacement)
Currently using blood thinners, since this could increase the risk of bruising
Pregnant women
Subjects with femoral retroversion (duck feet posture) significant enough to cause exoskeleton collisions while walking
PSCI 24-013 A RANDOMIZED PHASE II, DOUBLE-BLIND, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF AUTOGENE CEVUMERAN PLUS NIVOLUMAB VERSUS NIVOLUMAB AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA
This trial is looking at what happens to muscle invasive bladder cancer when adding cevumeran to Nivolumab
Participants will be required to keep all study appointments, tell the study doctor about all medications they are taking, report any side effects to the study doctor.
$202 for each visit completed
Surgical resection of muscle-invasive UC of the bladder or upper tract
Cisplatin ineligible
Absence of residual disease and absence of metastasis,
ECOG performance status of 0 or 1
Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment
Any prior neoadjuvant immunotherapy
Adjuvant chemotherapy or radiation therapy for UC following surgical resection
Absence of spleen
BCC022: Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
The purpose of this research is to evaluate the investigational drug, tipifarnib (a pill taken by mouth), in combination with the FDA approved drug, naxitamab, administered intravenously (IV; a liquid that continuously goes into your body through a tube that has been placed during a surgery into one of your veins).
You will be asked to come in for screening and at the start of each cycle (every 28 days), and at the end of study treatment to have tests done (these may include a physical exam, blood tests, and electrocardiogram [ECG]). During the first cycle you will need to have blood tests done weekly. You will also need to come in during Days 1-5 of each cycle to receive the study treatment. You will also have scans and a bone marrow biopsy (tissue sample) and aspirate (fluid and cells) done at the start of study, every 2 cycles, and at the end of study.
Age >12 months of age at enrollment
Age 6 years or older for safety run in
Currently receiving another investigational drug
A Confirmatory Phase 3 Mutlicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Topical HyBryte (Hypericin Sodium) and Visible-Light Activation for the Treatment of Cutaneous T-Cell Lymphoma (CTCL).
The purpose of this trial is to evaluate the safety and efficacy of 18 weeks of HyBryte (topical gel) treatment in combination with visible light therapy in subjects with cutaneous T-cell lymphoma when compared to placebo (no active ingredient). Cutaneous T-cell lymphoma (CTCL), of which the most common early stages are also known as mycosis fungoides (MF), is the most common type of T cell lymphoma. Participants will be enrolled in this trial for 30 weeks and will follow up at the clinic site every 4 weeks following the last trial treatment for a total of 12 weeks.
Participants will attend in person visits over 30 weeks. At different timepoints throughout the study participants will have their skin evaluated and photographed, have blood drawn, have an ECG done, and apply the study medication as directed by the study team.
Participants must have a minimum of 3 evaluable, discrete lesions
Participants must be willing to follow the clinical protocol and voluntarily give their written informed consent
Participants with extensive skin disease may not be eligible to participate; investigator will discuss during skin evaluation
Certain medical conditions may not be eligible to participate; study coordinator will discuss further.
Using the Socio-ecological Model to Assess Correlates of Physical Activity Participation Among Sexual and Gender Minority Adults
The purpose of this research is to examine correlates of physical activity participation among self-identifying sexual and/or gender diverse (e.g., non-heterosexual, non-cisgender) adults, guided by the socio-ecological model for health behavior (i.e., individual, social, communal, environmental).
Eligible participants will be invited to complete an open-link online survey that should take approximately 10 - 15 minutes to complete. There will be no other research activities after this unless individuals indicate that they would like to participate in a follow-up interview by indicating their interest on a separate form at the end of the survey. Participants who agree to take part in the interview (from the survey) will be contacted via email and an interview day/time will be scheduled. Three days before the interview, there will be an email reminder sent. Interviews will take place via Zoom at a day and time to be chosen by the participant.
Participants will be eligible to enter a drawing for a $50 gift card once they complete the survey. If you opt in to participate in the follow-up interview portion of the study, you will receive a $25 gift card for your time.
Identify as a sexual and/or gender diverse identity (i.e., non-heterosexual and/or non-cisgender).
Be able to participate in physical activities (e.g., exercise, sport).
Be able to read and write English.
Identify as heterosexual (i.e., straight).
Unable to participate in physical activities (e.g., exercise, sport)
Unable to read and write English.
PSCI 24-018 Phase 1, open label clinical trial to treat Stage IV cancer patients with multiple patient-specific mutated cell surface proteins with chimeric antibodies
This study will examine if giving patients their cells that have been modified in the lab will help control their cancer.
Subjects will be required to come to all visits. Each treatment will take 2-5 hours and there will be a total of 10 treatments over a 14 week period.
Subjects who have refractory or progressive disease after at least 1 line of systemic treatment
Subjects must have measurable disease
Known human immunodeficiency virus infection.
Subjects who have received any cytotoxic treatment within 3 weeks of antibody treatment.
Subjects who have received any radiotreatment to the primary sample site within the last 14 days
NUTRI-Beta Study: A Pilot Clinical Trial for Children with New Diagnosis of Stage 3 Type 1 Diabetes
This will be a 12-week single blinded, randomized, nutrition clinical trial for children with new diagnosis of stage 3 type 1 diabetes (clinical diagnosis of T1D). Beta cell function will be measured after 3 and 6 months.
Study participants in the intervention group will be required to follow the intake of specific foods and adhere to specific nutrition guidelines in addition to follow with a registered dietitian for 12 weeks (4 in person visits and 3 virtual visits). All these visits will be compensated. All study visits will be seen for a screening visit, an enrollment visit, 12-week visit and a 24-week visit. During the study visits, participants will undergo the following: physical exam/ demographic/social evaluation, clinical nutrition evaluation, nutrition counseling, dietary intake assessment, blood test collection, 2-hour Mixed Meal Tolerance Test (MMTT) and anthropometry.
$345
Age 6-17 years old, any gender
Attendance to the Pediatric diabetes clinic at Penn State Health in Hershey, PA
Positive antibodies for type 1 diabetes
History of seafood allergies and/or milk/dairy related allergies
Type 2 diabetes
Food sensory disorders
Pubertal children
Research on Survivorship Experiences: Disparities in cancer-related outcomes between rural and non-rural cancer survivors in the catchment areas of the Big 10 Cancer Research Consortium's Population Science Working Group
The objective of this cross sectional survey study is to describe the social and psychological outcomes of cancer survivors and characterize the disparities between rural and non-rural cancer survivors. We will collaborate will members of the Big 10 Cancer Research Consortium's Population Science Working Group to invite cancer survivors in rural and non-rural communities to complete one online survey, with each site targeting cancer survivors in their catchment areas. At Penn State, we will target recruitment to cancer survivors living in Pennsylvania. We plan to enroll 150 participants. It will take participants 30-40 minutes to complete the study and they will receive a $15 Amazon gift card for their time and effort.
If eligible, study participants will be asked to complete one online survey about their experience as a cancer survivor. Potential participants will first complete a REDCap screening form, if eligible, they will view the consent form. If they provide consent, they can complete the survey. A member of the Penn State study team will call the participant to confirm eligibility and once confirmed, will issue a $15 Amazon e-gift card. The entire study should take between 30-40 minutes to complete.
$15
non-metastatic cancer
1-5 years post completion of active treatment
no current evidence of cancer
living in certain counties in south central Pennsylvania
cannot speak or read English
unable to provide informed consent
less than 18 years old at time of cancer diagnosis
Dining Out in NYC: Using VR to investigate the influence of multisensory urban design factors on eating behavior in emerging adults
This study uses virtual reality to investigate how sensory aspects of an environment influence eating behavior. Specifically, subjects will be immersed in a virtual outdoor café environment and consume a standardized meal while being exposed to either a pleasant or unpleasant smell. Total food intake and mood will be measured following each visit.
Answer initial screening and demographics questionnaires. Two in-person visits to the lab to experience a VR setting and consume a provided meal. One visit will include a small hair sample. Answer questionnaires following the VR experience.
$20 in Amazon gift cards
Fluent in English
Not color blind or nose blind
No food allergies/sensitivities
No diagnosis of mental or physical disabilities that may affect appetite, eating behavior, or body awareness and balance (such as eating disorders, Major Depressive Disorder, epilepsy, and vertigo)
Not fluent in English
Color blind or nose blind
Self-reported food allergies/sensitivities
Have diagnosis of mental or physical disabilities that may affect appetite, eating behavior, or body awareness and balance (such as eating disorders, Major Depressive Disorder, epilepsy, and vertigo)